Predica Diagnostics B.V. a startup from the RadboudUMC, is active in the field of diagnostics, prognostics and prediction of treatment response in Women’s Health. Our platform technology is based on targeted RNA sequencing, making use of proprietary probes, next generation sequencing and unique algorithms. Predica Diagnostics first product, the CervicaDX test, allows non-invasive detection of cervical abnormalities in women who are at risk of developing cervical cancer. CervicaDx, will prevent overdiagnosis of women participating in population based cervical cancer screening programs, taking away unnecessary worries of HPV+ tested but healthy women, and reliably identify the women who need referral to a gynecologist, thereby streamlining the screening process and reducing redundance. After successful implementation of the CervicaDx test, Predica Diagnostics intends to expand its portfolio with diagnostic tests for other Women’s Health indications.